- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07284784
Studie Buntanetapu u účastníků s PD
Otevřená klinická studie zkoumající dlouhodobou bezpečnost přípravku Buntanetap při léčbě účastníků s Parkinsonovou chorobou
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Sarah MacCallum, BSN RN
- Telefonní číslo: 484-875-3192
- E-mail: maccallum@annovisbio.com
Studijní záloha kontaktů
- Jméno: Alexander Morin, PhD
- E-mail: morin@annovisbio.com
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- Nábor
- University of Alabama at Birmingham
-
Kontakt:
- Candace Cromer
- Telefonní číslo: 205-996-4034
- E-mail: candacecromer@uabmc.edu
-
Vrchní vyšetřovatel:
- Natividad Stover, M.D.
-
-
Arizona
-
Sun City, Arizona, Spojené státy, 85351
- Nábor
- Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
-
Vrchní vyšetřovatel:
- Sara Dhanani, M.D.
-
Kontakt:
- Serena Lowery
- Telefonní číslo: 623-832-6500
- E-mail: serena.lowery@bannerhealth.com
-
-
California
-
Fountain Valley, California, Spojené státy, 92708
- Nábor
- Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
-
Vrchní vyšetřovatel:
- Daniel Truong, M.D.
-
Kontakt:
- Evan Moreno-Davis
- Telefonní číslo: 714-378-5074
- E-mail: evan@pmdi.org
-
-
Colorado
-
Englewood, Colorado, Spojené státy, 80113
- Nábor
- Cenexel Rocky Mountain Clinical Research
-
Kontakt:
- Sally Modzelewski
- Telefonní číslo: 720-776-0092
- E-mail: s.modzelewski@cenexel.com
-
Vrchní vyšetřovatel:
- Meagen Salinas, M.D.
-
-
Connecticut
-
Stamford, Connecticut, Spojené státy, 06824
- Nábor
- New England Institute for Clinical Research (Ki Health Partners)
-
Kontakt:
- Valerija Misev
- Telefonní číslo: 125 203-914-1903
- E-mail: Valerija@neinh.com
-
Vrchní vyšetřovatel:
- Peter McAllister, M.D.
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- Nábor
- First Choice Neurology - Aventura Neurologic Associates
-
Vrchní vyšetřovatel:
- Jonathan Cross, M.D.
-
Kontakt:
- Jonathan Palmquist
- Telefonní číslo: 786-744-5596
- E-mail: jpalmquist@vintrials.com
-
Daytona Beach, Florida, Spojené státy, 32117
- Nábor
- Arrow Clinical Trials
-
Kontakt:
- Vinoothna Moluguri
- Telefonní číslo: 386-316-6152
- E-mail: vmoluguri@arrowtrials.com
-
Vrchní vyšetřovatel:
- David Billmeier, M.D.
-
DeLand, Florida, Spojené státy, 32720
- Nábor
- Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
-
Vrchní vyšetřovatel:
- Bruce Rankin, D.O.
-
Kontakt:
- Erica Santoni
- Telefonní číslo: 4608 1-386-785-2400
- E-mail: erica.santoni@accelclinical.com
-
Miami, Florida, Spojené státy, 33172
- Nábor
- Professional Research Center
-
Kontakt:
- Saylet Corbera
- Telefonní číslo: 786-359-4091
- E-mail: RamirezMD@professionalresearchcenter.com
-
Miami, Florida, Spojené státy, 33015
- Zatím nenabíráme
- Ezy Medical Research Co.
-
Kontakt:
- Priscilla Hernandez
- Telefonní číslo: 786-483-8162
- E-mail: phernandez@ezytrials.com
-
Ocala, Florida, Spojené státy, 34470
- Nábor
- Renstar Medical Research
-
Vrchní vyšetřovatel:
- Annette Nieves, M.D.
-
Kontakt:
- Sebastian Mesa
- Telefonní číslo: 352-629-5800
- E-mail: sebastian.mesa@renstar.net
-
Tampa, Florida, Spojené státy, 33613
- Nábor
- University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
-
Kontakt:
- Erica Botting
- Telefonní číslo: 813-974-8026
- E-mail: ericabotting@usf.edu
-
Vrchní vyšetřovatel:
- Robert Hauser, M.D., MBA
-
Winter Park, Florida, Spojené státy, 32789
- Nábor
- Conquest Research
-
Kontakt:
- Fabiola Perez
- Telefonní číslo: 407-916-0060
- E-mail: fabiola.perez@conquestresearch.com
-
Vrchní vyšetřovatel:
- Rekha Gandhi, M.D.
-
-
Georgia
-
Decatur, Georgia, Spojené státy, 30030
- Nábor
- iResearch Atlanta
-
Kontakt:
- Elizabeth Davis
- Telefonní číslo: 404-537-1281
- E-mail: e.davis@cenexel.com
-
Vrchní vyšetřovatel:
- Kimball Johnson, M.D.
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46256
- Nábor
- Josephson Wallack Munshower Neurology, P.C.
-
Vrchní vyšetřovatel:
- Kristi George, M.D.
-
Kontakt:
- Tammy Root
- Telefonní číslo: 1-317-573-6061
- E-mail: troot@jwmneuro.com
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- Nábor
- University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
-
Kontakt:
- Kelly Lyons
- Telefonní číslo: 913-588-7159
- E-mail: klyons@kumc.edu
-
Vrchní vyšetřovatel:
- Rajesh Pahwa, M.D.
-
-
Michigan
-
Farmington Hills, Michigan, Spojené státy, 48334
- Nábor
- Quest Research Institute
-
Vrchní vyšetřovatel:
- Aaron Ellenbogen, D.O.
-
Kontakt:
- Savannah Carra
- Telefonní číslo: 248-957-8940
- E-mail: savannah.carra@questri.com
-
-
New York
-
New York, New York, Spojené státy, 10019
- Nábor
- Mount Sinai Hospital
-
Vrchní vyšetřovatel:
- Joohi Jimenez-Shahed, M.D.
-
Kontakt:
- Sofya Glazman
- Telefonní číslo: 646-493-1862
- E-mail: sofya.glazman@mountsinai.org
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Nábor
- Duke Department of Neurosurgery
-
Vrchní vyšetřovatel:
- Kyle Mitchell, M.D.
-
Kontakt:
- Vera George
- Telefonní číslo: 919-668-3885
- E-mail: vera.george@duke.edu
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43210
- Nábor
- The Ohio State University Wexner Medical Center
-
Vrchní vyšetřovatel:
- Zachary Jordan, M.D.
-
Kontakt:
- Victoria Miller
- Telefonní číslo: 614-688-8672
- E-mail: victoria.miller@osumc.edu
-
-
Oklahoma
-
Tulsa, Oklahoma, Spojené státy, 74136
- Nábor
- The Movement Disorder Clinic of Oklahoma
-
Kontakt:
- Elise Gibson
- Telefonní číslo: 918-392-4530
- E-mail: mdcclinicaltrials@gmail.com
-
Vrchní vyšetřovatel:
- Kevin Klos, M.D.
-
-
Pennsylvania
-
Willow Grove, Pennsylvania, Spojené státy, 19090
- Nábor
- Abington Neurology
-
Vrchní vyšetřovatel:
- David Weisman, M.D.
-
Kontakt:
- Brian Weingartner
- Telefonní číslo: 130 215-957-9250
- E-mail: brian.weingartner.ana@gmail.com
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29401
- Nábor
- Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
-
Kontakt:
- Sandra Wilson
- Telefonní číslo: 843-792-3223
- E-mail: wilsosan@musc.edu
-
Vrchní vyšetřovatel:
- Vanessa Hinson, M.D., PhD
-
-
Tennessee
-
Cordova, Tennessee, Spojené státy, 38018
- Nábor
- Neurology Clinic, P.C.
-
Kontakt:
- Ye Liu
- Telefonní číslo: 901-747-1111
- E-mail: yliu@neuroclinic.org
-
Vrchní vyšetřovatel:
- Kendrick Henderson, M.D.
-
Memphis, Tennessee, Spojené státy, 38157
- Nábor
- Veracity Neuroscience LLC
-
Kontakt:
- Hannah Touliatos
- Telefonní číslo: 901-604-0345
- E-mail: hannah@veracityneuroscience.com
-
Vrchní vyšetřovatel:
- Mark LeDoux, M.D., PhD
-
-
Texas
-
Round Rock, Texas, Spojené státy, 78681
- Nábor
- Central Texas Neurology
-
Kontakt:
- Koni Lopez
- Telefonní číslo: 512-218-1222
- E-mail: k.lopez@ctncpa.org
-
Vrchní vyšetřovatel:
- Elizabeth Peckham, M.D.
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22903
- Nábor
- University of Virginia Health System (UVAHS) - Adult Neurology Clinic
-
Vrchní vyšetřovatel:
- Binit Shah, M.D.
-
Kontakt:
- Lauren Miller
- Telefonní číslo: 434-982-6599
- E-mail: fdk5dn@uvahealth.org
-
-
Washington
-
Spokane, Washington, Spojené státy, 99202
- Nábor
- Inland Northwest Research
-
Vrchní vyšetřovatel:
- Jason Aldred, M.D.
-
Kontakt:
- Aaron Dahl
- Telefonní číslo: 509-960-2818
- E-mail: adahl@inwresearch.com
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Nábor
- Medical College of Wisconsin
-
Kontakt:
- Shelby Schold
- Telefonní číslo: 414-955-0698
- E-mail: sschold@mcw.edu
-
Vrchní vyšetřovatel:
- Karen Blindauer, M.D.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and
a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.
b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.
i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.
-
Have a support person who will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
- Standard of care anti-parkinsonian medication,
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
- Mood-stabilizing psychotropic agents including, but not limited to, lithium,
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Good general health with no disease expected to interfere with the study.
Exclusion Criteria:
-
Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).
-
A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.
-
Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54
-
Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.
-
Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).
-
Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
A learning disability or developmental delay.
-
Participants whom the site PI deems to be otherwise ineligible.
-
A known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified microcrystalline cellulose
- Dibasic calcium phosphate dihydrate
- Mannitol
- Stearic acid
- Hypromellose (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Is currently pregnant, breast-feeding, and/or lactating.
-
Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Cohort 1 - buntanetap
Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun |
buntanetap capsules 30 mg by mouth daily |
|
Experimentální: Cohort 2 - buntanetap
Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. |
buntanetap capsules 30 mg by mouth daily |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Safety of buntanetap
Časové okno: 36-months of treatment
|
Safety assessments of participants with PD receiving treatment with buntanetap |
36-months of treatment
|
|
Adverse Events (AE)
Časové okno: 36-months of treatment
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention |
36-months of treatment
|
|
Treatment Emergent Adverse Events (TEAE)
Časové okno: 36-months of treatment
|
TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state |
36-months of treatment
|
|
Serious Adverse Events (SAE)
Časové okno: 36-months of treatment
|
SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly |
36-months of treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Laurie Sanders, Ph.D., Duke Clinical Research Institute
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ANVS-25002
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .